Each year, hundreds of thousands of people visit Arches National Park to go hiking in the summer months, hoping for long, sunny days filled with outdoor adventure. However, many of these visitors ...

Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug Application for Uzedy extended-release injectable suspension ...

TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two ...

Teva’s sales guidance, on the other hand, topped forecasts for 2025. The company expects to generate revenues between $16.8 billion to $17.4 billion this year, powered by the continued gains of ...

Axsome Therapeutics (NASDAQ:AXSM) stock rallied 15% in morning trading on news it has settled patent litigation with Teva (NYSE:TEVA) over its antidepressant drug Auvelity. Axsome (NASDAQ ...

Also Read: Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As ‘Top Pick For 2025’ In the UC cohort of the RELIEVE UCCD study ...

Considering Teva’s extended-release version of Austedo won a key approval in 2023, ramped-up competition in 2025 is something the team at Evercore ISI had anticipated. Even so, this year’s fir ...

From travel bags to comfortable footwear and handy accessories, these Amazon 3.3 deals have everything you need for your ...

Axsome Therapeutics has resolved the patent infringement lawsuit that it filed against Teva Pharmaceutical Industries after the generics powerhouse sought FDA approval for a copycat to Axsome's ...

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The settlement resolves all patent litigation related to Axsome’s ...